<DOC>
	<DOC>NCT00650871</DOC>
	<brief_summary>A study to investigate the effects of GW679769 on sleep and cognition. Potential subjects participate in a clinical screening visit and a two-night PSG recording session in the sleep laboratory. Eligible subjects then participate in three separate two-night PSG sessions in which they are randomized to receive placebo or one of two doses of GW679769 60 minutes prior to bedtime, one treatment for each session in a balanced order. Each treatment session is separated by a two-week drug-free period and occur on the same day of the week. A safety follow-up visit occurs 2 weeks after the last treatment session.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Healthy male and female subjects with primary insomnia with normal EG may be eligible for inclusion. clinically significant physical or psychiatric illness or abnormal sleep patterns.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>GW679769,</keyword>
	<keyword>sleep,</keyword>
	<keyword>cognitive function,</keyword>
	<keyword>primary insomnia,</keyword>
	<keyword>polysomnography.</keyword>
</DOC>